Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was somehow refreshing and relaxing, because that now-familiar routine of Zoom and Skype meetings has predictably returned. What can you do? Despite the crush of dizzying events, the world keeps spinning. So please join us as we cope with a delicious cup of stimulation. Our choice today is cinnamon dolce. Meanwhile, here is a fresh stack of tidbits for you to peruse. Hope your day goes well, and stay safe. …

Eli Lilly (LLY) has begun a study of its Olumiant rheumatoid arthritis drug in patients hospitalized for Covid-19, Reuters writes. The drug is being tested to see if it can reduce deaths and lessen severity of the virus. Lilly scientists believe the drug could help suppress a potentially lethal immune response to Covid-19 called a “cytokine storm” and reduce the ability of the virus to reproduce in infected cells. The trial began dosing patients last week and plans to enroll around 400 patients globally.


The German government will pay approximately $337 million for a 20% stake in CureVac, which is working on a Covid-19 vaccine, DW reports. To safeguard German ownership of the two coronavirus vaccine developers in the country — CureVac and BioNTech — the federal government gave itself new powers in May to reject foreign takeover bids for health care companies. Two months earlier, the Trump administration tried to lure CureVac to do research in the U.S.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!